Stockhead’s resident Health and Biotech expert Tim Boreham is putting down the microscope and picking up the microphone for another installment of The Health Kick Podcast.
In this episode Tim interviews Michael Harsh, non-executive director at Imagion Biosystems (ASX:IBX).
Imagion Biosystems is developing a diagnostic imaging tool called Magsense, which is based on injecting nanoparticles with magnetic fields to detect tumors such as breast cancers.
Listen to the podcast.
Imagion Initiates Manufacturing of MagSense® Drug for Phase 2 Clinical Study on HER2+ Breast Cancer
MELBOURNE – Imagion Biosystems (Company) (ASX : IBX), a company dedicated to improving healthcare outcomes through the early detection of cancer, is pleased to announce